MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

Search

Zentalis Pharmaceuticals Inc

Fermé

1.55 -2.52

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.53

Max

1.67

Chiffres clés

By Trading Economics

Revenu

21M

-27M

Marge bénéficiaire

-176.706

Employés

166

EBITDA

9.7M

-36M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+322.01% upside

Dividendes

By Dow Jones

Prochains Résultats

10 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

21M

121M

Ouverture précédente

4.07

Clôture précédente

1.55

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 oct. 2025, 21:10 UTC

Principaux Mouvements du Marché

Kezar Life Sciences Shares Surge After Break with FDA, Restructuring Plan

16 oct. 2025, 19:03 UTC

Acquisitions, Fusions, Rachats

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- 2nd Update

16 oct. 2025, 17:58 UTC

Acquisitions, Fusions, Rachats

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- Update

16 oct. 2025, 17:12 UTC

Résultats

Ray-Ban Maker EssilorLuxottica's Revenue Surges to Quarterly Record -- Update

16 oct. 2025, 17:12 UTC

Acquisitions, Fusions, Rachats

Canada Signals Limited Concern Over US Government Stakes in Canadian Miners

16 oct. 2025, 16:59 UTC

Acquisitions, Fusions, Rachats

Airbus's Takeover of Spirit AeroSystems Plants Gets French Antitrust Clearance

16 oct. 2025, 23:44 UTC

Market Talk

Gold Climbs Amid Safe-Haven Demand -- Market Talk

16 oct. 2025, 23:42 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Declines -- Market Talk

16 oct. 2025, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

16 oct. 2025, 22:15 UTC

Résultats

China Tower: Results Supported by Higher Contributions From Energy, Smart Tower Business >0788.HK

16 oct. 2025, 22:15 UTC

Résultats

China Tower 9-Mos Rev CNY74.32B Vs. CNY72.45B >0788.HK

16 oct. 2025, 22:15 UTC

Résultats

China Tower 9-Mos Net CNY8.71B Vs. Net CNY8.15B >0788.HK

16 oct. 2025, 22:02 UTC

Market Talk

Global Equities Roundup: Market Talk

16 oct. 2025, 22:02 UTC

Market Talk

Santos Drifts Into 'Oversold Territory' -- Market Talk

16 oct. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 oct. 2025, 20:50 UTC

Market Talk
Résultats

Health Care Roundup: Market Talk

16 oct. 2025, 20:23 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 oct. 2025, 20:23 UTC

Market Talk

Recession Risks to Push Canada Toward October Rate Cut -- Market Talk

16 oct. 2025, 20:20 UTC

Résultats

These Stocks Moved the Most Today: TSMC, Salesforce, HPE, F5, United Airlines, Travelers, J.B. Hunt, Praxis Precision, and More -- Barrons.com

16 oct. 2025, 20:08 UTC

Acquisitions, Fusions, Rachats

Jack in the Box to Sell Del Taco With Big Markdown. The Stock Plunged. -- Barrons.com

16 oct. 2025, 19:37 UTC

Acquisitions, Fusions, Rachats

Crypto Industry Dives Deeper Into Prediction Markets as Kraken Buys Exchange -- Barrons.com

16 oct. 2025, 19:26 UTC

Résultats

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 oct. 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Falls on Mild Weather, Ample Storage -- Market Talk

16 oct. 2025, 19:23 UTC

Market Talk

Oil Falls As Oversupply Concerns Outweigh India News -- Market Talk

16 oct. 2025, 19:23 UTC

Résultats

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 oct. 2025, 18:35 UTC

Market Talk
Résultats

Charles Schwab Logs Another Quarter of Record Revenues, Earnings -- Market Talk

16 oct. 2025, 18:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 oct. 2025, 18:31 UTC

Market Talk

Global Equities Roundup: Market Talk

16 oct. 2025, 18:31 UTC

Market Talk

Charles Schwab Readies Spot Crypto Trading -- Market Talk

16 oct. 2025, 16:57 UTC

Market Talk

Oil Futures Lose Ground as EIA Reports Crude Stock Build -- Market Talk

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

322.01% hausse

Prévisions sur 12 Mois

Moyen 6.71 USD  322.01%

Haut 10 USD

Bas 4 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

8 ratings

4

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

1.23 / 1.45Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat